Long-term use of common heartburn pills is tied to higher kidney and dementia risk

Proton-pump inhibitors, the widely used medications that quell heartburn and acid reflux, are among the most commonly taken drugs in the world, available both by prescription and over the counter. A growing body of research has linked their long-term use to higher risks of kidney problems and, in some studies, dementia, prompting doctors to urge caution about taking them for years without review. The associations do not prove the drugs cause those conditions, but they have reshaped how physicians think about prescribing them.

What proton-pump inhibitors do

Proton-pump inhibitors, or PPIs, work by shutting down the pumps in the stomach lining that produce acid. That makes them highly effective for conditions driven by excess acid, including gastroesophageal reflux disease, ulcers and inflammation of the esophagus. Common examples include omeprazole, esomeprazole, lansoprazole and pantoprazole. The National Institute of Diabetes and Digestive and Kidney Diseases describes PPIs as a mainstay for treating acid reflux and GERD, conditions that affect a large share of adults.

Their effectiveness and easy availability have made them extraordinarily popular, and that is precisely where the concern arises. The drugs were designed and studied for relatively short courses, often eight weeks or less, but many people take them continuously for years, sometimes without a clear ongoing medical need. It is this prolonged, often unsupervised use that the newer research has scrutinized.

The kidney findings

Several large observational studies have reported that long-term PPI use is associated with a higher risk of chronic kidney disease and acute kidney injury. Researchers have proposed that the drugs may occasionally trigger a form of kidney inflammation, and that repeated or unnoticed episodes could contribute to lasting damage over time. Because chronic kidney disease often progresses silently, such harm can accumulate without obvious symptoms until kidney function is substantially reduced. Guidance on protecting kidney health from the same federal institute emphasizes monitoring for people with risk factors for kidney disease, a category that some studies suggest may include long-term PPI users.

The kidney associations have been consistent enough across multiple studies to draw clinical attention, though they remain associations. Observational research can identify a statistical link but cannot by itself establish that the drug caused the outcome, because people who take PPIs long-term may differ in other ways, such as age, overall health or other medications, that also affect kidney function.

The dementia question

The possible link to dementia has been more contested. Some studies, particularly earlier analyses of older adults, reported that regular PPI users had a higher rate of dementia diagnoses, and researchers speculated about mechanisms, including effects on the clearance of amyloid proteins in the brain or on absorption of vitamin B12, a nutrient important for nerve health. Subsequent studies, however, produced conflicting results, with some finding no clear association once other factors were accounted for. The evidence on dementia is therefore weaker and less consistent than the kidney findings, and reporting compiled by health-focused outlets such as the health section of ScienceDaily has reflected that ongoing scientific debate.

Beyond kidneys and cognition, long-term PPI use has been tied in various studies to other potential harms, including deficiencies in vitamin B12 and magnesium, an increased risk of certain intestinal infections such as Clostridioides difficile, and a modestly higher risk of bone fractures. As with the kidney and dementia data, most of these findings come from observational research and describe associations rather than proven cause and effect.

Why doctors still prescribe them

Despite the concerns, PPIs remain valuable and, for many patients, the best available treatment. For serious conditions such as bleeding ulcers, severe reflux or Barrett’s esophagus, the benefits clearly outweigh the potential risks, and stopping the drugs abruptly can cause a rebound surge in acid. The clinical response to the research has not been to abandon PPIs but to use them more deliberately: prescribing the lowest effective dose for the shortest necessary duration, and periodically reassessing whether continued use is warranted. The Food and Drug Administration, which regulates these drugs, maintains labeling and safety information for approved medications, including PPIs.

Physicians increasingly recommend “deprescribing” for patients who have been on PPIs for years without a strong ongoing indication, tapering the dose to avoid rebound acid and, where appropriate, switching to alternatives such as lifestyle changes or less potent acid reducers. For milder reflux, dietary and behavioral measures, weight management and avoiding trigger foods can reduce or eliminate the need for daily acid suppression.

Weighing the evidence

The overall message from the research is one of caution rather than alarm. The kidney associations are reasonably consistent and biologically plausible, the dementia link is uncertain and disputed, and none of the findings establish that PPIs directly cause these outcomes. For patients, the practical takeaway is to use the drugs when genuinely needed, at the lowest effective dose, and to review long-term use with a clinician rather than continuing indefinitely by default.

Ongoing research continues to refine the picture, including studies designed to better separate the drugs’ effects from the characteristics of the people who take them. Until that work resolves the open questions, the prudent course endorsed by many physicians is straightforward: treat real acid-related disease with PPIs confidently, but avoid taking powerful acid-suppressing medication for years on end without a clear and current reason.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview